Alliance Pharma Regulatory News (APH)

2 Mar 2006 07:00

Alliance Pharma PLC02 March 2006 For Immediate Release 2 March 2006 ALLIANCE PHARMA PLC ("Alliance" or "the Company") Notification of Preliminary Results On behalf of our client Alliance Pharma plc (AIM: APH), the emerging specialitypharmaceutical company, we notify that they will be reporting their PreliminaryResults for the ten months ended 31 December, 2005 on Thursday 23 March, 2006. As notified at the time of the Interims results in November last year, thecompany has changed its year end from February to December to bring it into linewith its peer companies. For further information:Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed emerging specialitypharmaceutical company based in Chippenham, Wiltshire, UK. The company has astrong track record of acquiring the rights to established niche brands andowns, or shares, the rights to 30 branded pharmaceutical products and continuesto explore opportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to pharmaceutical wholesalers whichservice both hospital and retail pharmacies with their prescriptionrequirements. Alliance Pharma is also developing novel products for sleep disorders and theinduction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange